Industry: Research reagents
Abeome discovers and develops monoclonal antibodies (mAbs) to help diagnose and treat cancer and autoimmune diseases. A major company focus is improving the development cycle for faster mAb discovery.
Abeome’s proprietary technology for mAb discovery is called DiSH, and it offers greater efficiency in identifying desired monoclonals. One of the company’s recent products, AbeoMouse™, is a transgenic mouse with an enhanced immune response.
The therapeutic antibody market is one of the fastest-growing market segments in biotech and pharmaceuticals. Abeome will license its platform technology to partner companies.
Company website: Abeome